The French drugmaker is including a special security as part of its sweetened $10 bln offer to buy Medivation. Rob Cyran and Jeffrey Goldfarb discuss the pitfalls of this so-called CVR.
from Reuters Video: Breakingviews http://ift.tt/29OPwOt
via
IFTTT
No comments:
Post a Comment